Slingshot members are tracking this event:

AbbVie Presents Initial Data from Pivotal Phase-3 Trial Evaluating the Efficacy and Safety of HUMIRA (adalimumab) for Moderate to Severe Fingernail Psoriasis in Adult Patients at Psoriasis 2016 Congress

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
- Data from Phase 3 randomized, placebo controlled trial demonstrates that 46.6 percent of adult patients with moderate to severe psoriasis treated with HUMIRA achieved at least a 75 percent improvement in their moderate to severe fingernail psoriasis 
- Fingernail psoriasis occurs in up to 55 percent of people living with psoriasis and up to 70 percent of people living with psoriatic arthritis(1)
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 07, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fingernail Psoriasis, Psoriatic Arthritis, Adalimumab, Humira